Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.32 | N/A | -6.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.32 | N/A | -6.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains optimistic about the company's long-term prospects, focusing on strategic partnerships. They acknowledged the EPS miss but emphasized their commitment to innovation.
Management highlighted ongoing partnerships as a key driver for future growth.
They expressed confidence in their pipeline despite the EPS miss.
Despite missing EPS expectations, Ligand Pharmaceuticals saw a positive stock reaction, rising 5.04%. This increase may reflect investor confidence in the company's future potential, driven by ongoing partnerships and a strong pipeline. The lack of revenue data and guidance leaves some uncertainty, but management's optimistic tone could help maintain investor interest.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018